Cybin Inc (CLXPF) Prices 8.8M Share Offering at $3.40/sh
- Indexes close up more than 1% as investors assess Fed news
- China Tells Local Authorities to Prepare For a 'Possible Storm' and Prevent Unrest as Evergrande Crisis Unravels - WSJ
- Salesforce (CRM) Raises FY22 Revenue Guidance; Initiates FY23 Revenue
- Oil prices rise, hit 2-month highs on supply worries
- IDFA Seen as a 'Real Headwind' for Facebook (FB) but Analysts Remain Positive
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Cybin Inc. (OTCQB: CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, announced today the pricing of its previously announced overnight marketed offering (the “Offering”) of an aggregate of 8,824,000 common shares in the capital of the Company (the “Shares”) at a price of $3.40 per Share for total gross proceeds of $30,001,600.
Cantor Fitzgerald Canada Corporation and Canaccord Genuity Corp., as joint bookrunners, co-led the syndicate of underwriters for the Offering, which included H.C. Wainwright & Co., LLC, Roth Canada, ULC, and Stifel Nicolaus Canada Inc. (collectively, the “Underwriters”).
The Offering is expected to close on or about August 3, 2021, or such other date as the Underwriters and the Company may agree, and completion of the Offering will be subject to market and other customary conditions, including approval of the Neo Exchange Inc. (the “NEO Exchange”).
The Company has granted the Underwriters a 30-day option to purchase up to an additional 1,323,600 Shares, representing 15% of the Shares issued pursuant to the proposed Offering on the same terms and conditions for market stabilization purposes and to cover over-allotments (the “Over-Allotment Option”). The Over-Allotment Option may be exercised in whole or in part as determined by the Underwriters.
The Company intends to use the net proceeds from the Offering for general corporate and working capital purposes.
The Shares will be offered in each of the provinces of Canada, excluding Quebec, pursuant to a prospectus supplement to the Company’s short form base shelf prospectus dated July 5, 2021 (the “Base Shelf Prospectus”). The Shares will not be offered or sold in the United States or to U.S. persons except pursuant to Rule 144A or in such other manner as to not require registration under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). Prior to forming an investment decision, prospective investors should read the Base Shelf Prospectus and the documents incorporated by reference therein, including any marketing materials, which are available on the Company’s SEDAR profile available at www.sedar.com.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities to be offered have not been, and will not be registered under the U.S. Securities Act or under any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PAVmed's (PAVM) Lucid Diagnostics Files For a Proposed IPO
- Toast (TOST) IPO Prices Above-Range at $40, Pushing Valuation to ~$20 Billion
- Cantor Fitzgerald Sees No Negative Read-Through to Novan (NOVN) From Verrica CRL
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Related EntitiesStifel, Cantor Fitzgerald, Canaccord Genuity, H.C. Wainwright, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!